ClinicalTrials.Veeva

Menu

CASTLE (Clopidogrel And Serum Troponin Level Elevation)

Sanofi logo

Sanofi

Status and phase

Completed
Phase 3

Conditions

Thrombosis

Treatments

Drug: Clopidogrel

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

Primary Objective: To test if 600 mg of clopidogrel loading dose administered ≥ 6 and ≤ 24 hours prior to PCI produce a greater decrease of periprocedural release of biochemical markers (CK, CK-MB, and troponin-T and/or I) of myocardial necrosis, compared to 300 mg loading dose, given ≥ 6 and ≤ 24 hours prior to PCI or 600 mg loading dose of clopidogrel, administered immediately (≤ 45 minutes) before PCI.

Enrollment

155 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients having symptomatic coronary artery disease with objective evidence of ischemia (eg, symptoms of angina pectoris, positive stress test results or dynamic electrocardiographic (ECG) changes).
  • Patients undergoing stent implantation

Exclusion criteria

  • Any known contraindication to the use of aspirin or clopidogrel.
  • Patients receiving clopidogrel within 10 days, thrombolytics within 24 hours or receiving oral anticoagulation therapy
  • Elective administration of IIb/IIIa inhibitors.
  • Cardiogenic shock
  • Acute MI< 24 hours
  • BP systolic <100 mmHg
  • Left ventricular ejection fraction < 30%
  • Heart failure, NYHA class III or IV
  • Severe renal insufficiency (creatinine > 3.0 mg/dL)
  • Platelet count <100,000/mm³
  • Target lesion in a venous bypass graft
  • Target lesion in a chronic occlusion

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

155 participants in 3 patient groups

1
Experimental group
Description:
300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
Treatment:
Drug: Clopidogrel
Drug: Clopidogrel
2
Experimental group
Description:
600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
Treatment:
Drug: Clopidogrel
Drug: Clopidogrel
3
Experimental group
Description:
600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
Treatment:
Drug: Clopidogrel
Drug: Clopidogrel

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems